(Q37291850)

19 August 2017

1 reference

title

The global impact of vaccination against hepatitis B: a historical overview (English)

1 reference

19 August 2017

1 reference

2

Pierre Van Damme

1 reference

19 August 2017

Alessandro R Zanetti

1

1 reference

19 August 2017

Daniel Shouval

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

9 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26

1 reference

19 August 2017

issue

49

1 reference

19 August 2017

page(s)

6266-6273

1 reference

Genetic variability in hepatitis B viruses

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B virus: significance of genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Global status of hepatitis B immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Human hepatitis B vaccine from recombinant yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Safety of immunization and adverse events following vaccination against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccination and the risk of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Does the hepatitis B vaccine cause multiple sclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccination: how long does protection last?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Persistence of specific antibodies after hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccination: to boost or not to boost?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Detecting hepatitis B surface antigen mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B variant in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Vaccine-induced escape mutant of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Effect of hepatitis B virus mutants on efficacy of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Emergence of hepatitis B virus S gene mutant in a liver transplant recipient.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Universal hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

7 January 2021

Hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccination: how to reach risk groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B virus infection: epidemiology and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Twelve-year follow-up study of hepatitis B immunization of Senegalese infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Legend of hepatitis B vaccination: the Taiwan experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Mass vaccination against hepatitis B in infants in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Vaccination against hepatitis B: the Italian strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Chronic hepatitis D: a vanishing Disease? An Italian multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Immunomodulatory therapy for chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Immunization against hepatitis B through adoptive transfer of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.056

10.1016/J.VACCINE.2008.09.056

7 January 2021

Identifiers

DOI

1 reference

release_h2mmbpim5fhtpebxhlob5gfhku

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h2mmbpim5fhtpebxhlob5gfhku

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference